According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are $4.05 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-12-31 | $4.05 B | 9.34% |
2022-12-31 | $3.70 B | 21.26% |
2021-12-31 | $3.05 B | 27.78% |
2020-12-31 | $2.39 B | 149.97% |
2019-12-31 | $0.95 B | 250.55% |
2018-12-31 | $0.27 B | 19.51% |
2017-12-31 | $0.22 B | -33.36% |
2016-12-31 | $0.34 B | 181.28% |
2015-12-31 | $0.12 B | -15.02% |
2014-12-31 | $0.14 B | -4.56% |
2013-12-31 | $0.15 B | -2.14% |
2012-12-31 | $0.15 B | -6.38% |
2011-12-31 | $0.16 B | -30.26% |
2010-12-31 | $0.23 B | -22.54% |
2009-12-31 | $0.30 B | -13.94% |
2008-12-31 | $0.35 B | 19.66% |
2007-12-31 | $0.29 B | 658.71% |
2006-12-31 | $38.83 M | 6.19% |
2005-12-31 | $36.56 M | 83.17% |
2004-12-31 | $19.96 M | -67.74% |
2003-12-31 | $61.89 M | 198.16% |
2002-12-31 | $20.75 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Novartis NVS | $53.19 B | 1,213.29% | ๐จ๐ญ Switzerland |
Sanofi SNY | $57.61 B | 1,322.36% | ๐ซ๐ท France |
Regeneron Pharmaceuticals REGN | $7.10 B | 75.46% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | $2.40 B | -40.62% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | $9.48 M | -99.77% | ๐บ๐ธ USA |
OPKO Health
OPK | $0.62 B | -84.63% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $35.35 B | 772.80% | ๐ฎ๐ฑ Israel |
Arrowhead Pharmaceuticals
ARWR | $0.45 B | -88.83% | ๐บ๐ธ USA |